FDA proposes MRD-negative and complete response endpoints to fast-track multiple myeloma drug approvals, pushing deeper molecular results over ORR.

From Nylon to Neural Networks Defining the Landscape The Hawthorne Effect in the Bathroom Manual Toothbrush vs.

A division of the U.S. Agency for International Development eliminated by Trump administration cuts last year was reborn ...

By Dr. Sanchari Sinha Dutta, Ph.D. A landmark randomized trial shows that preparing the uterus using natural ovulation ...

Late-Breaking Science Abstract LB 032 - In a phase III clinical trial in China, stroke patients treated intravenously with loberamisal, a novel neuroprotective medication, daily for 10 days starting ...

BioStem remains committed to advancing evidence-based innovation in wound care through rigorous clinical research and real-world data analysis, supported by its proprietary BioRetain ® process and ...

In combined analysis (n = 39), the average wound closure rate was 98%, and all 19 patients previously diagnosed for potential ...

The FDA Center for Drug Evaluation and Research has accepted a letter of intent for the first biomarker for idiopathic ...

POTOMAC, MARYLAND / ACCESS Newswire / February 2, 2026 / IGC Pharma, Inc. ("IGC" or the "Company"), today reported it has reached approximately 70% of planned patient enrollment in its Phase 2 CALMA ...

The practical takeaway for executives is direct. Treat flexibility like any other operating system.

Albert Bourla: 2025 was a very good year for Pfizer Inc. I'm very pleased with strong execution to deliver and, frankly, overdeliver on our financial commitments. If successful, we will substantially ...

PHILADELPHIA, PENNSYLVANIA / ACCESS Newswire / January 23, 2026 / Medicus Pharma Ltd. (NASDAQ:MDCX) (“Medicus” or the ...